José M Mato Selected Research

Glycine N-Methyltransferase (Glycine Sarcosine N-Methyltransferase)

11/2019	miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease.
9/2012	Hepatoma cells from mice deficient in glycine N-methyltransferase have increased RAS signaling and activation of liver kinase B1.
7/2011	High-frequency ultrasound imaging for longitudinal evaluation of non-alcoholic fatty liver disease progression in mice.
9/2010	Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease.
7/2010	Fatty liver and fibrosis in glycine N-methyltransferase knockout mice is prevented by nicotinamide.
4/2008	Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

José M Mato Research Topics

Disease

28	Neoplasms (Cancer) 01/2021 - 08/2002
27	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 02/2002
26	Fibrosis (Cirrhosis) 10/2022 - 02/2002
23	Liver Neoplasms (Liver Cancer) 01/2022 - 04/2005
20	Non-alcoholic Fatty Liver Disease 10/2022 - 08/2002
18	Liver Diseases (Liver Disease) 11/2020 - 07/2002
15	Fatty Liver 09/2020 - 03/2003
10	Inflammation (Inflammations) 01/2022 - 07/2010
9	Carcinogenesis 01/2021 - 08/2002
9	Colonic Neoplasms (Colon Cancer) 01/2015 - 07/2007
8	Liver Cirrhosis (Hepatic Cirrhosis) 11/2020 - 07/2002
6	Cholestasis 02/2020 - 10/2012
5	Cholangiocarcinoma 01/2021 - 01/2017
3	COVID-19 01/2022 - 01/2020
3	Mitochondrial Diseases (Mitochondrial Disease) 12/2019 - 10/2012
3	Obesity 06/2015 - 08/2002
3	Alcoholic Liver Diseases (Alcoholic Liver Disease) 10/2006 - 07/2002
2	Infections 01/2022 - 01/2021
2	Erythropoietic Porphyria (Congenital Erythropoietic Porphyria) 01/2021 - 01/2018
2	Prostatic Neoplasms (Prostate Cancer) 01/2020 - 01/2018
2	Alcoholic Fatty Liver 08/2019 - 04/2010
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2022
1	Tyrosinemias (Tyrosinemia) 02/2021
1	Rare Diseases (Rare Disease) 01/2021
1	Congenital, Hereditary, and Neonatal Diseases and Abnormalities (Congenital Disorders) 01/2021

Drug/Important Bio-Agent (IBA)

32	S-Adenosylmethionine (Ademetionine)IBA 01/2022 - 02/2002
23	Methionine AdenosyltransferaseIBA 01/2021 - 08/2002
19	Proteins (Proteins, Gene)FDA Link 10/2022 - 03/2003
16	Methionine (L-Methionine)FDA Link 08/2019 - 07/2002
9	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2010
9	Messenger RNA (mRNA)IBA 01/2019 - 03/2002
7	EnzymesIBA 10/2022 - 11/2002
7	Pemetrexed (MTA)FDA Link 01/2015 - 11/2004
6	Choline (Choline Chloride)IBA 01/2021 - 01/2003
6	ProteomeIBA 11/2020 - 03/2003
6	Triglycerides (Triacylglycerol)IBA 09/2020 - 08/2002
6	Glycine N-Methyltransferase (Glycine Sarcosine N-Methyltransferase)IBA 11/2019 - 04/2008
4	Phosphotransferases (Kinase)IBA 01/2021 - 02/2009
4	MicroRNAs (MicroRNA)IBA 01/2021 - 11/2016
4	LipidsIBA 09/2020 - 08/2002
4	Fatty Acids (Saturated Fatty Acids)IBA 11/2019 - 07/2010
4	ProhibitinsIBA 01/2019 - 12/2010
4	MitogensIBA 07/2013 - 03/2007
4	DNA (Deoxyribonucleic Acid)IBA 07/2010 - 04/2003
3	Phospholipids (Phosphatides)FDA LinkGeneric 01/2022 - 01/2021
3	Lipoproteins (Lipoprotein)IBA 01/2022 - 01/2021
3	UbiquitinIBA 11/2020 - 01/2017
3	Biological ProductsIBA 10/2020 - 01/2004
3	Glucose (Dextrose)FDA LinkGeneric 09/2020 - 09/2011
3	CarbonIBA 01/2020 - 09/2011
3	Glutathione (Reduced Glutathione)IBA 11/2016 - 08/2002
3	HomocysteineIBA 05/2011 - 07/2002
2	Protons (Proton)IBA 01/2022 - 01/2018
2	PorphyrinsIBA 01/2022 - 01/2020
2	ApolipoproteinsIBA 01/2022 - 01/2021
2	acetoacetic acid (acetoacetate)IBA 02/2021 - 01/2016
2	Pharmaceutical PreparationsIBA 01/2021 - 01/2018
2	aramcholIBA 09/2020 - 11/2017
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2019 - 02/2012
2	Ethanol (Ethyl Alcohol)IBA 12/2019 - 01/2013
2	methylallyl trisulfide (MATS)IBA 08/2019 - 01/2018
2	VLDL LipoproteinsIBA 06/2019 - 03/2015
2	Sirtuin 1IBA 01/2019 - 08/2013
2	obeticholic acidIBA 12/2018 - 01/2018
2	CollagenIBA 12/2018 - 11/2012
2	pevonedistatIBA 01/2017 - 02/2015
2	Insulin-Like PeptidesIBA 11/2016 - 06/2011
2	Phosphatidylcholines (Phosphatidylcholine)IBA 06/2015 - 02/2015
2	AntigensIBA 11/2012 - 04/2012
2	Transaminases (Aminotransferases)IBA 10/2012 - 04/2008
2	Peptides (Polypeptides)IBA 09/2012 - 03/2003
2	5'-methylthioadenosineIBA 09/2012 - 07/2009
2	Insulin-Like Growth Factor I (IGF-1)IBA 06/2011 - 03/2002
2	MethyltransferasesIBA 07/2010 - 08/2009
2	LeptinIBA 03/2010 - 02/2008
2	Protein Isoforms (Isoforms)IBA 03/2008 - 12/2005
1	Phospholipases (Phospholipase)IBA 10/2022
1	very low density lipoprotein triglycerideIBA 10/2022
1	ribosomal protein L18IBA 01/2022
1	Glycoproteins (Glycoprotein)IBA 01/2022
1	ribosomal protein S3IBA 01/2022
1	fumarylacetoacetateIBA 02/2021
1	HydrolasesIBA 02/2021
1	succinylacetoneIBA 02/2021
1	HDL LipoproteinsIBA 01/2021
1	IronIBA 01/2021
1	Sorafenib (BAY 43-9006)FDA Link 01/2021
1	Glycerophospholipids (Phosphoglycerides)IBA 11/2020
1	Carbon Tetrachloride (Tetrachloromethane)IBA 11/2020
1	SphingolipidsIBA 11/2020
1	Proliferating Cell Nuclear Antigen (PCNA)IBA 11/2020
1	Extracellular Matrix ProteinsIBA 11/2020
1	NF-kappa B (NF-kB)IBA 11/2020
1	T0901317IBA 11/2020
1	4- (4- dihexadecylaminostyryl)- N- methylpyridium (DiA)IBA 10/2020
1	Arginine (L-Arginine)FDA Link 10/2020
1	Lysine (L-Lysine)FDA Link 10/2020

Therapy/Procedure

5	Chemoprevention 01/2018 - 07/2009
4	Therapeutics 11/2019 - 04/2012
3	Ligation 01/2019 - 01/2018